Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

14.94 +0.37 (+2.54%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 256,266
Open 15.16
Bid (Size) 15.00 (1,300)
Ask (Size) 15.56 (100)
Prev. Close 14.57
Today's Range 14.72 - 15.53
52wk Range 5.005 - 19.14
Shares Outstanding 101,102,152
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Small-Cap Slump: Russell 2000 Tumbles as Sticky Inflation Data Revives 'Higher-for-Longer' Fears
The Russell 2000 index, the primary benchmark for American small-cap stocks, suffered a significant sell-off on Wednesday, January 7, 2026, as a batch of conflicting economic data sparked fears that... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire

Performance

YTD
-15.9%
-15.9%
1 Month
-0.9%
-0.9%
3 Month
-5.7%
-5.7%
6 Month
+61.9%
+61.9%
1 Year
-11.3%
-11.3%

More News

Read More
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals ↗
Via Benzinga
News headline image
Atara Biotherapeutics Announces Changes to Its Board of Directors
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces Pricing of $16 Million Offering
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs ↗
Via Benzinga
News headline image
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Nasdaq Down 150 Points; Morgan Stanley Earnings Top Estimates ↗
Via Benzinga
News headline image
Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip ↗
Via Stocktwits
News headline image
Crude Oil Down 1%; Bank of America Posts Upbeat Earnings ↗
Via Benzinga
News headline image
US Stocks Edge Lower; Retail Sales Increase Less Than Expected ↗
Via Benzinga
News headline image
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)
From Atara Biotherapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Atara Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, Atara Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does Atara Biotherapeutics, Inc. - Common Stock trade on?
Atara Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Atara Biotherapeutics, Inc. - Common Stock?
The ticker symbol for Atara Biotherapeutics, Inc. - Common Stock is ATRA on the Nasdaq Stock Market
What is the current price of Atara Biotherapeutics, Inc. - Common Stock?
The current price of Atara Biotherapeutics, Inc. - Common Stock is 14.94
When was Atara Biotherapeutics, Inc. - Common Stock last traded?
The last trade of Atara Biotherapeutics, Inc. - Common Stock was at 01/07/26 04:00 PM ET
What is the market capitalization of Atara Biotherapeutics, Inc. - Common Stock?
The market capitalization of Atara Biotherapeutics, Inc. - Common Stock is 1.51B
How many shares of Atara Biotherapeutics, Inc. - Common Stock are outstanding?
Atara Biotherapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.